Eton noncompliant with SEC reporting after Increlex acquisition; unable to provide audited financials

Eton Pharmaceuticals, Inc.

Acquisition of Increlex from Ipsen closed Dec 19, 2024; must be accounted for as business combination.
Historical financial statements for Increlex do not exist; Eton cannot create them.
Filed SEC waiver request for Item 9.01 financial statement requirement.
Noncompliance renders Eton ineligible for Form S-3 and substantially curtails capital raising.
Until waiver granted or financials filed, no new registration statements can be declared effective.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.